Journal Home
Search for

Volume 136, Issue 2, Pages 83-91 (15 September 2005)


View previous. 2 of 19 View next.

No association found between 158 Val/Met polymorphism of the COMT gene and schizophrenia with minor physical anomalies

Eun-Jeong Jooa, Seong-Hoon Jeongb, Yong-Min Ahnc, Kyu-Young Leed, Se Chang Yoone, Eui-Joong Kima, Seon-Uk Kima, Soo-Churl Choc, Yong Sik KimcCorresponding Author Informationemail address

Received 19 June 2004; received in revised form 22 November 2004; accepted 16 December 2004.

Abstract 

The catechol-O-methyl transferase (COMT) gene has been a promising candidate in genetic research on schizophrenia because of its function in dopamine metabolism and its location on chromosome 22q11.2, which may be implicated in both schizophrenia and velocardiofacial syndrome (VCFS). To explore the possible genetic contribution of COMT to the development of schizophrenia, we focused on the subgroup of patients with schizophrenia characterized by minor physical anomalies as a phenotype and the 158 Val/Met polymorphism as a genotype. Since some physical anomalies are found in both schizophrenia and VCFS, schizophrenia patients with minor physical anomalies could represent the putative subgroup of schizophrenia linked to a disruption in neurodevelopment. Genotyping for the 158 Val/Met (472 G>A) polymorphism in the COMT gene was done for 239 patients with schizophrenia and 248 normal controls. Our analysis did not yield any significant between-group differences in terms of either allele or genotype frequency. We also could not find any association between the COMT gene and the schizophrenia subgroup with minor physical anomalies, although there was a significant difference in Waldrop total scores between the patients with schizophrenia and the normal controls. Analyses of subgroups based on other clinical variables also did not reveal significant differences. Overall, this study does not support the hypothesis that the 158 Val/Met polymorphism in the COMT gene is associated with schizophrenia in Koreans.

a Department of Psychiatry, Eulji University School of Medicine, Daegeon, South Korea

b Department of Psychiatry, Dongguk University College of Medicine, Gyeongju, South Korea

c Department of Psychiatry and Behavioral Science and Institute of Human Behavioral Medicine, Seoul National University College of Medicine, 28 Yongon-Dong Chongno-Gu, Seoul, 110-744, South Korea

d Department of Psychiatry, Seoul National University Hospital, Seoul, South Korea

e Department of Psychiatry, Sungkyunkwan University School of Medicine, Seoul, South Korea

Corresponding Author InformationCorresponding author. Tel.: +82 2 2072 2204; fax: +82 2 744 7241.

PII: S0165-1781(05)00165-4

doi:10.1016/j.psychres.2004.12.011


View previous. 2 of 19 View next.